^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CEA-targeted CAR-T immunotherapy

    Related drugs:
    10d
    PBC102: A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=48, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P1 trial
    |
    cyclophosphamide • fludarabine IV • C-13-60
    10d
    CEA CAR-T Therapy After Cytoreduction in Colorectal Cancer Patients With Peritoneal Metastases (clinicaltrials.gov)
    P1, N=12, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P1 trial
    |
    cyclophosphamide • fludarabine IV • C-13-60
    3ms
    CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=108, Recruiting, Chongqing Precision Biotech Co., Ltd
    New P1 trial
    |
    cyclophosphamide • fludarabine IV • C-13-60
    7ms
    CAR-T Therapy Targeting CEA in Advanced CEA-Positive Lung Cancer (clinicaltrials.gov)
    P1, N=60, Recruiting, Chongqing Precision Biotech Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open • IO biomarker
    |
    cyclophosphamide • fludarabine IV • C-13-60
    7ms
    CAR-T Therapy Targeting CEA in Advanced CEA-Positive Lung Cancer (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, Chongqing Precision Biotech Co., Ltd
    New P1 trial • IO biomarker
    |
    cyclophosphamide • fludarabine IV • C-13-60
    7ms
    EVEREST-1: A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression (clinicaltrials.gov)
    P1/2, N=160, Active, not recruiting, A2 Biotherapeutics Inc. | Recruiting --> Active, not recruiting | Trial completion date: Dec 2028 --> Dec 2026
    Enrollment closed • Trial completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    A2B530
    10ms
    PBC039: A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=60, Active, not recruiting, Weijia Fang, MD | Recruiting --> Active, not recruiting | Trial completion date: May 2025 --> Dec 2025
    Enrollment closed • Trial completion date • IO biomarker
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    cyclophosphamide • fludarabine IV • C-13-60
    10ms
    Study of CEA Targeting CAR-T in the Treatment of CEA-Positive Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=72, Recruiting, Weijia Fang, MD
    New P1 trial
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    cyclophosphamide • fludarabine IV • C-13-60
    11ms
    A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer (clinicaltrials.gov)
    P1, N=48, Recruiting, Chongqing Precision Biotech Co., Ltd
    New P1 trial • IO biomarker
    |
    CEACAM5 positive
    |
    cyclophosphamide • fludarabine IV • C-13-60
    1year
    EVEREST-1: initial safety data from a seamless phase 1/2 study of A2B530, a logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting HLA-LOH (SITC 2024)
    β2M shRNA, beta–2–microglobulin short–hairpin RNA; CD, cluster of differentiation; EF1α, elongation factor–1 alpha; LIR, leukocyte immunoglobulin–like receptor; scFv, single–chain variable fragment; T2A, thosea asigna virus 2ADownload figure Open in new tab Download powerpoint Abstract 588 Figure 2 EVEREST-1 study design. BOIN, Bayesian optimal interval design; PCLD, preconditioning lymphodepletion; RP2D, recommended phase 2 dose
    Clinical • P1/2 data • CAR T-Cell Therapy
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CEACAM5 (CEA Cell Adhesion Molecule 5) • B2M (Beta-2-microglobulin) • GZMB (Granzyme B)
    |
    CEACAM5 expression • HLA-A*02
    |
    Tempus HLA-LOH assay
    |
    A2B530
    over1year
    EVEREST-1: A seamless phase 1/2 study of A2B530, a carcinoembryonic antigen (CEA) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH). (ASCO 2024)
    P1/2 | "Clinical Trial Registration Number: NCT05736731"
    Clinical • P1/2 data • CAR T-Cell Therapy
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    A2B530
    almost2years
    An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=9, Recruiting, China Medical University, China | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    CEACAM5 expression • CEACAM5 overexpression
    |
    cyclophosphamide • fludarabine IV • anti-CEA-CAR-T